Kovilen Sawmynaden

Loading metrics Open Access Peer-reviewed Research Article Abstract Human epidermal growth factor receptor-2 (HER2) is a well-recognised biomarker associated with 25% of breast cancers. In most cases, early detection and/or treatment correlates with an increased chance of survival. This study, has identified and characterised a highly specific anti-HER2 single-domain antibody (sdAb), NM-02, as a potential theranostic tool.

Interleukin-16 (IL-16) is reported to be a chemoattractant cytokine and modulator of T-cell activation, and has been proposed as a ligand for the co-receptor CD4. The secreted active form of IL-16 has been detected at sites of T 1-mediated inflammation, such as those seen in autoimmune diseases, ischemic reperfusion injury (IRI), and tissue transplant rejection.

Author contributions: GH and MC coordinated the study and wrote the paper. GH and RC purified IL-16 protein, EC, JA and KV purified c14.1Fab and CD4 proteins, and GH determined the c14.1Fab-IL-16tr complex X-ray structure. GH and FM designed, performed and analysed the NMR experiments shown in Figures 2 and supplementary Figure 2. JA designed and performed the ELISA assay shown in supplementary Figure 1. WC provided the c14.1Fab DNA construct.